RYUL KIM1,#, JOO KYUNG PARK2,#, MINSUK KWON3, MINAE AN4, JUNG YONG HONG1, JOON OH PARK1, SUNG HEE LIM1,*, SEUNG TAE KIM1,*
Oncology Research, Vol.33, No.1, pp. 57-65, 2025, DOI:10.32604/or.2024.049054
- 20 December 2024
Abstract Background: Immune checkpoint inhibitors (ICIs) are effective in a subset of patients with metastatic solid tumors. However, the patients who would benefit most from ICIs in biliary tract cancer (BTC) are still controversial. Materials and methods: We molecularly characterized tissues and blood from 32 patients with metastatic BTC treated with the ICI pembrolizumab as second-line therapy. Results: All patients had microsatellite stable (MSS) type tumors. Three of the 32 patients achieved partial response (PR), with an objective response rate (ORR) of 9.4% (95% confidence interval [CI], 2.0–25.2) and nine showed stable disease (SD), exhibiting a disease… More >
Login
Register
